Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like talquetamab represent promising new options, particularly for patients with BCMA-refractory disease. Key challenges include managing cytokine release syndrome, developing optimal sequencing strategies, addressing drug resistance, and improving accessibility and affordability of novel therapies.
Panelist discusses the clinical patient, a 72-year-old man who was previously diagnosed 6 years ago with multiple myeloma, 60% plasma cells, which he presents to his oncologist after 5 prior treatment regimens. The patient also has had 2 episodes of pneumonia and multiple episodes of bronchitis over the prior 10 years.
Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field.
Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes.
Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non–small cell lung cancer that has developed resistance to osimertinib.
Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024, shedding light on potential strategies for managing EGFR-mutated and MET-amplified non–small cell lung cancer.
Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.
Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years.
Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.
Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma.
Panelists discuss how the management of adverse events differs between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor plus TKI (ICI+TKI) combinations, including any notable differences in adverse effect profiles among various ICI plus TKI regimens used in treating metastatic renal cell carcinoma.
Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.
Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.
Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.
Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.
Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.
Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations for first-line treatment of metastatic renal cell carcinoma, considering key factors that influence their decision-making process and drawing insights from recent clinical trials such as CheckMate 9ER, KEYNOTE-426, and CLEAR.
Panelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ongoing research into novel therapeutic strategies and combination approaches to overcome resistance mechanisms.
Panelists discuss how the efficacy and safety profiles of various treatment options for intermediate/poor-risk metastatic renal cell carcinoma compare, including cabozantinib monotherapy, nivolumab plus cabozantinib combination, nivolumab plus ipilimumab combination, and other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations.
Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, considering various factors that influence decision-making for newly diagnosed patients.
Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.
Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.
Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.
Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.
Panelists discuss how ESMO 2024 presented important updates on primary end points and progression-free survival data from recent clinical studies.
Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.
Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory end points for evaluating a new cancer treatment.
Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent chronic graft-versus-host disease (cGVHD), highlighting its potential in challenging cases.
Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease (cGVHD), exploring its role in advancing treatment when earlier options have been exhausted.